CompletedPhase 2NCT06470464

Thalidomide Combined With Chemotherapy in the Treatment of Relapsed or Refractory Yolk Sac Tumor

Studying Tumor of testis and paratestis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Shandong First Medical University
Principal Investigator
Jingfu Wang, MD
Shandong Cancer Hospital and Institute
Intervention
Thalidomide combined with TGA chemotherapy (nab-paclitaxel + gemcitabine+ epirubicin)(drug)
Enrollment
20 enrolled
Eligibility
1-18 years · All sexes
Timeline
20212024

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06470464 on ClinicalTrials.gov

Other trials for Tumor of testis and paratestis

Additional recruiting or active studies for the same condition.

See all trials for Tumor of testis and paratestis

← Back to all trials